New KEYTRUDA Data to be Presented at 17th World Conference on Lung Cancer Highlight Research Across the Spectrum of Thoracic Malignancies New KEYTRUDA Data to be Presented at 17th World Conference on Lung Cancer Highlight Research Across the Spectrum of Thoracic Malignancies Merck , known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA , the company's anti-PD-1 therapy, across multiple thoracic malignancies, including non-small cell lung cancer , small cell lung cancer and malignant pleural mesothelioma, will be presented at the 17th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Vienna, Austria, Dec. 4-7 .
